Drug Search Results
More Filters [+]

Matuzumab

Alternative Names: matuzumab
Latest Update: 2023-03-21
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: EGFR Binder

Novel Mechanism: Yes

Modality: Antibody

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: Merck KGaA
Company Location: GERMANY HRB 6164 I8
Company CEO: Belen Garijo
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Matuzumab

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 2: Esophageal Cancer|Gastrointestinal Cancer|Non-Small-Cell Lung Cancer|Colorectal Cancer|Adenocarcinoma

Phase 1: Gastrointestinal Cancer|Adenocarcinoma|Esophageal Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2006-000899-32

P2

Completed

Non-Small-Cell Lung Cancer

2009-06-05

MATRIX EG

P2

Completed

Gastrointestinal Cancer|Esophageal Cancer

2008-07-31

MAURICE

P2

Completed

Colorectal Cancer

2007-10-30

EMD 72000-031

P2

Completed

Non-Small-Cell Lung Cancer

2007-07-31

Recent News Events